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57 ABSTRACT 
A plasmid bearing a cDNA copy of the genome of bovine 
viral diarrhea virus (BVDV), chimeric derivatives of the 
plasmid and a method of producing an infectious bovine 
Viral diarrhea virus using the plasmid are disclosed. The 
invention relates to a plasmid DNA molecule that replicates 
easily in E. coli and contains a Sufficient portion of the 
genome of BVDV, cloned as cDNA, to be a suitable tem 
plate to produce RNA in vitro which, upon transfection into 
bovine cells, gives rise to infectious BVDV. The BVDV 
created by the process of the invention can be engineered for 
use as a Vector in many advantageous applications. 
21 Claims, 10 Drawing Sheets 
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PLASMID BEARING A CDNA COPY OF THE 
GENOME OF BOVINE WRAL DIARRHEA 
VIRUS, CHIMERIC DERIVATIVES 
THEREOF, AND METHOD OF PRODUCING 
AN INFECTIOUS BOVINE WRAL 
DARRHEAVIRUS USING SAID PLASMID 
This application claims the benefit of U.S. Provisional 
Application No. 60/018,246 filed May 24, 1996. 
RIGHTS IN THE UNITED STATES 
GOVERNMENT 
This invention was made with federal support under NRI 
grant 92-37204-7959 from the USDA. The United States 
government has certain rights to the invention. 
BACKGROUND OF THE INVENTION 
This invention relates to plasmids for viruses, methods for 
engineering the plasmids and methods for analyzing virus 
replication. 
The bovine viral diarrhea virus, or BVDV, is the prototype 
species in the Pestivirus genus of the Flaviviridae. Positive 
strand RNA viruses, such as the poliovirus and the BVDV, 
have a genome consisting of a Single molecule of RNA. Pure 
RNA extracted from either highly concentrated and purified 
poliovirus or BVDV can be transfected into a susceptible 
cell, which results in the production of infectious progeny 
virus by the cell. A homogeneous preparation of viral RNA 
molecules is infectious upon transfection. 
The usefulness of RNA molecules from BVDV and 
poliovirus is limited because they are many thousand nucle 
otides in length and cannot be engineered in vitro to change 
their Sequence using current technology. By contrast, DNA 
molecules of Similar length, cloned into plasmids, can be 
manipulated with restriction enzymes and Synthetic oligode 
Oxynucleotides to obtain any desired Sequence. 
It is known that the entire RNA sequence of some viruses 
can be cloned into a plasmid. Such plasmids can be used to 
produce RNA molecules in vitro that mimic the properties of 
the RNA extracted from the purified virus. The RNA syn 
thesized in Vitro using a plasmid DNA as a template pro 
duces the virus upon transfection into Susceptible cells. 
Plasmids with this property are known as “infectious 
clones.” 
BVDV remains enzootic in cattle populations throughout 
the World. Current vaccines are either relatively unsafe or 
ineffective in control and eradication programs. Efficient 
reverse genetics approaches using an infectious molecular 
clone of the BVDV genome may contribute to the develop 
ment of rationally-designed Safe and efficacious vaccines. 
The construction of an infectious molecular clone of 
BVDV, its Subsequent modification to introduce a sequence 
tagged site and the production of a chimeric virus expressing 
a Surface glycoprotein from a different Strain, manipulating 
the BVDV genome in vitro and its potential effectiveness for 
reverse genetic analyses of pestivirus are described herein 
after. 
SUMMARY OF THE INVENTION 
Accordingly, it is an object of the invention to provide a 
novel plasmid. 
It is a further object of the invention to provide a novel 
method for engineering a plasmid. 
It is a further object of the invention to provide a novel 
method for engineering the genome of BVDV for vaccine 
development. 
1O 
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It is a still further object of the invention to provide a 
novel method for the analysis of virus replication. 
It is a still further object of the invention to provide a 
novel approach for vaccine development. 
It is a still further object of the invention to provide a 
BVDV infectious clone. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The above noted and other features of the invention will 
be better understood from the following detailed description, 
in which: 
FIG. 1 is a block diagram illustrating the process of 
forming BVDV clNA genomic clone; 
FIG. 2 is a diagram of a portion of the process of FIG. 1; 
FIG. 3 is a diagram of another portion of the process of 
FIG. 1; 
FIG. 4 is a diagram of another portion of the process of 
FIG. 1; 
FIG. 5 is a diagram of another portion of the process of 
FIG. 1; 
FIG. 6 is a diagram of another portion of the process of 
FIG. 1; 
FIG. 7 is a table describing starting plasmids for the 
production of the chimeric virus of this invention; and 
FIG. 8 is a diagram illustrating the nucleotide Sequence 
alignment of the region of the BVDV genome between 
nucleotide 2040 and 3600 from 3 different viruses: the two 
parental and the chimeric derivative. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention relates to a plasmid DNA molecule 
that replicates easily in Escherichia coli bacteria and con 
tains a sufficient portion of the genome of BVDV, cloned as 
cDNA, to be a suitable template to produce RNA in vitro, 
which upon transfection into bovine cells, gives rise to 
infectious BVDV. The BVDV created by this process can be 
engineered as a vector for use in the following applications: 
(1) the development of attenuated or avirulent virus 
Strains for use as live vaccines, 
(2) the addition of foreign Sequences encoding proteins of 
immunological interest, Such as proteins from other para 
Sites or viruses, Such as foot and mouth disease, leading to 
the use of BVDV as a vector to vaccinate against other 
infectious or parasitic diseases, 
(3) the addition of immunostimulatory molecules, Such as 
C3d complement molecule interleukins and the like; 
(4) the development of marker vaccines with a charac 
teristic deletion which allows the discrimination between 
vaccinated and infected animals by retrospective Serological 
tests, 
(5) the development of sequence-tagged BVDV vaccines 
which allow identification of the origin of the BVDV in the 
event of alleged vaccine-associated outbreaks, 
(6) the mapping of attenuating mutations leading to 
avirulent phenotypes, and 
(7) the identification of novel antiviral targets against 
pestivirus and related flaviviruses by creation of suitable 
chimeric viruses. 
Five plasmids from the work of Collett et al., “Molecular 
Cloning and Nucleotide Sequence of the Pestivirus Bovine 
Viral Diarrhea Virus,” Virology 165, 191-199, were used as 
a Starting material for the present invention. Cultures of 
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these plasmids are maintained in Several private cultures, 
one of which is in the refrigerator (Room VBS 151) in the 
Veterinary Basic Science Building, Department of Veteri 
nary Science, University of Nebraska, Lincoln, Nebr. 68583, 
designated: (1) pBV-18; (2) pBV-116b; (3) pBV-D79; (4) 
pBV-F2; and (5) pBVSD2-3". These cultures will be made 
available upon granting of the patent. These plasmids are 
described in FIG. 7. 
From these plasmids, six vectors have been constructed: 
(1) a plasmid containing a chimeric genome of BVDV, Strain 
NADL, with Singer Strain E2/gp53 glycoprotein, propagated 
in E. coli strain GM119, culture designated as pVVNADL 
Singp, maintained in a private repository at the campus of 
the University of Nebraska, in a refrigerator (Room VBS 
151), in the Veterinary Basic Science Building, Department 
of Veterinary Science, Lincoln, Nebr. 68503 (ATCC No 
97572); (2) a plasmid containing sequence-tagged genome 
of BVDV, strain NADL, in E. coli strain GM110, in a culture 
designated as pVVNADL delta Dra maintained in a private 
repository at the campus of the University of Nebraska, in a 
refrigerator (Room VBS 151), in the Veterinary Basic Sci 
ence Building, Department of Veterinary Science, Lincoln, 
Nebr. 68503 (ATCC No. 97573); (3) a plasmid pVVNADL 
in a culture designated as pVVNADL maintained in a 
private repository at the campus of the University of 
Nebraska, in a refrigerator (Room VBS 151), in the Veteri 
nary Basic Science Building, Department of Veterinary 
Science, Lincoln, Nebr. 68503; (4) a Chimeric BVDV. 
i-VVNADL-Singp, in a culture designated as i-VVNADL 
maintained in a private repository at the campus of the 
University of Nebraska, in a refrigerator (Room VBS 151), 
in the Veterinary Basic Science Building, Department of 
Veterinary Science, Lincoln, Nebr. 68503 (ATCC No. 
VR2529); (5) a virus i-VVNADL delta Dra in a culture 
designated as i-VVNADL delta Dra maintained in a private 
repository at the campus of the University of Nebraska, in a 
refrigerator (Room VBS 151), in the Veterinary Basic Sci 
ence Building, Department of Veterinary Science, Lincoln, 
Nebr. 68503; and (6) a virus i-VVNADL in a culture 
designated as i-VVNADL maintained in a private repository 
at the campus of the University of Nebraska, in a refrigerator 
(Room VB5 151), in the Veterinary Basic Science Building, 
Department of Veterinary Science, Lincoln, Nebr. 68583. 
Missing Sequences were incorporated at four locations 
and the plasmids were joined to construct a single plasmid 
with the entire BVDV genome as cDNA: pVVNADL. An E. 
coli, strain GM119, (genotype: F-SupE44 lacY1 galK2 
galT22 metB1 dam-3 dcm-6 tSX-78 lambda-) was used in the 
preferred embodiment because of the increased plasmid 
stability provided by this E. coli strain. The infectious clone 
plasmid (pVVNADL) is not stable in some other E. coli 
hosts, such as MC1061, JM105, JM109, Sure, DH.5a. The 
precise molecular basis of the increased stability in GM119 
is unknown. The BVDV genome can be custom-tailored in 
the infectious clone plasmid pVVNADL, or one of its 
precursors: pBV18-F2 and p50Meu-3". Two examples are as 
follows: 
(a) BVDV with a unique sequence tag, i-VVNADL delta 
Dra, was created which is neutral with respect to 
phenotypic properties of BVDV; and 
(b) a chimeric BVDV virus, i-VVNADL Singp, which 
replicates like a wild-type (WT) virus in spite of the 
chimeric nature of its genome and its antigenic differ 
ences detected with monocolonal antibodies. 
As part of this process, the 5' and 3' termini of the BVDV 
genome were reconstructed. This reconstruction includes the 
addition of BVDV genomic Sequences missing or corrupted, 
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the tailoring of Signals of RNA transcription, and the engi 
neering of cleavage Sites for linearization of the DNA prior 
to transcription. A Single nucleotide deletion present in the 
glycoprotein-encoding region of the virus (nt 2702) is 
repaired by replacement of a Small fragment amplified from 
viral cdNA by RT-PCR. Sequence information present in all 
of the plasmids representing each region of the BVDV 
genome was verified and repaired. 
Functional integrity of the T7 promotor, the 5'-UTR, and 
the ORF of one intermediate plasmid which encompasses 
the 5'-5.5 kb of the BVDV genome is verified by transfection 
of linearized pBV18-F2 plasmid DNA into bovine cells 
infected with a vaccinia virus producing T7 RNA poly 
merase. Because the T7 promoter in pBV18-F2 directs the 
Synthesis of RNA transcripts representing the region of the 
BVDV genome encoding for the structural proteins of the 
virus, transfected bovine cells were probed with monoclonal 
antibodies (Mabs) to the viral glycoproteins. The integrity of 
the ORF was confirmed and it was determined that the 3' 
UTR of the virus is not required for translation. After this, 
a full-length cDNA clone, termed pVVNADL was obtained 
by joining a fragment of DNA derived from p3V18-F2 to 
plasmid P5DMeu-3'. 
RNA transcripts from the full-length BVDV genome 
clones in pVVNADL were generated using the following 
procedure: DNA was linearized with SacII restriction 
endonuclease, which cleaves pVVNADL at the 3'-end of the 
BVDV genome. This DNA was used as template for in vitro 
transcription with T7 RNA polymerase with or without 
removing the 3'-overhand left by SacII. Transcription with 
the cap analog and transfection of the capped RNA were also 
tested. Production of RNA molecules identical to the BVDV 
genome With an exact 3' end was ascertained by gel elec 
trophoresis and Northern Blotting. RNA synthesized in vitro 
was used to transfect EBTr cells by electroporation. 
Controls included the electroporation of a transcription 
mix lacking template DNA or T7 DNA polymerase. Fol 
lowing electroporation, cells were distributed into dishes 
containing glass coverslips to allow fixation and immunof 
luorescence Staining. Cells were monitored for possible 
Signs of cytopathology. Monolayers on glass coverSlips were 
fixed at 24 and 48 hours after electroporation and Stained 
with Mab to the p80/N53 protein. Supernatant fluid from 
these wells was collected to check the phenotype of the 
rescued virus. RNA transcripts made in vitro were 
infectious, yielding ~10 TCIDso/ug. RNA transcribed in the 
presence of the cap analog had less infectivity than 
uncapped RNA. RNA Synthesis with cap analog and reduced 
concentration of GTP very likely results in truncated tran 
scripts. The phenotype of the virus rescued from pVVNADL 
transcripts, termed i-VVNADL, was studied in vitro. 
Infectious BVDV was produced by cells transfected with 
uncapped RNA transcribed in vitro. The DNA template for 
RNA production consisted of a plasmid containing the entire 
genome of BVDV, cloned as cDNA. The internal ribosome 
entry site element in the 5'-untanslated region (UTR) of the 
viral genome and the functional 5’- and 3'-termini in viral 
genomic RNA BVDV rescued from the infectious cl)NA 
clone had an in vitro phenotype virtually identical to the WT 
parent, the NADL strain of BVDV. 
A genomic deletion of a Single codon in the infectious 
clone, encoding glutamic acid at position 1600 of the viral 
polyprotein, gave rise to Sequence tagged BVDV readily 
identified by restriction fragment length polymorphism 
analysis of reverse transcription-polymerase chain reaction 
(RT-PCR) amplicons. Suitability of the molecular clone of 
BVDV for genomic manipulations was shown by Substitu 
6,001,613 
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tion of the major envelope glycoprotein E2/gp53 with that of 
the Singer Strain, giving rise to a chimeric virus. The 
predicted change in antigenic Structure of the chimeric virus 
was identified with strain-specific Mabs by neutralization or 
immunofluorescence assay. 
Embryonic bovine trachea (EBTr) cells and the NADL 
strain of BVDV were obtained from the American Type 
Culture Collection (CCL-44 and VR-534). This strain of 
BVDV was isolated from the spleen of a naturally-occurring 
fatal case of BVDV infection. 
In this process, a set of five plasmids bearing overlapping 
cDNAS from the BVDV genome are used to assemble a full 
length copy of the viral genome in a single plasmid DNA 
molecule, following Standard procedures. These five plas 
mids are the five plasmids maintained in five cultures in the 
refrigerator (Room VB5 151) in the Veterinary Basic Sci 
ence Building, Department of Veterinary Science, Univer 
sity of Nebraska, Lincoln, Nebr. 68583 designated as 
pBV18, BV116b, pBVD79, pBVF2 and pBVSD2,3. 
In FIG. 1, there is shown a flow diagram of an assembly 
proceSS comprising Seventeen intermediate cloning Steps to 
join the original cDNA clones, to incorporate the missing 5'- 
and 3'-termini of the viral genome, to restore the altered 
BVDV genomic Sequence, as well as to tailor Signals for 
runoff RNA transcription in vitro. 
As shown in FIG. 1, five plasmids pBV-18; p.3V-116P; 
pBVD-79; pBV-F2; and pBVSD2-3' are converted to 
pBV18-T7-C1aI, pBV116-C1aI, pBVDF2-79 and pBVSD 
3'-M1 uI as shown in step 11, 13, 15 and 17 respectively. 
These five intermediate plasmids are converted to the plas 
mid pVVNADL. 
In FIG. 2, there is shown a conversion of the pBV-18 
plasmid to pBV18-T7-C1a. In this process, the plasmid 12, 
pBV18, has a T7 promotor and missing nt added at 5'-end 
terminus of the BVDV genome in step 12. A T7 synthetic 
promotor flanked by EcoRI Avril restrictive site cohesive 
ends is ligated (covalently bonded by DNA ligase) as shown 
by a plasmid 22, pBV18-T7. A unique C1al site is added by 
ligating a Synthetic oligonucleotide part at EcoRI 
C1 alEcoRI to result in a plasmid 24, pBV18-T7-C1 al. This 
plasmid is digested with Bsu36I and MscI to obtain a DNA 
fragment, labeled 26 pBV18-T7-C1al, which will be joined 
to a fragment derived from PBV 106-F2 (plasmid 42 in FIG. 
6). 
In FIG. 3, there is shown a conversion of the plasmid 14, 
pBV116b, to the plasmid 32, p3V116-C1 al. In this process, 
plasmid 14 is modified by removal of DNA fragment 
extracting from the ECORV site to the REC II site, followed 
by replacement with an analogous fragment derived from 
BVDV RNA by RT-PCR. The reason to replace this frag 
ment from this plasmid was the presence of a deletion at 
position 2702. The result of the experiment is plasmid 28, 
pBV116c. The plasmid 28 has modified by the insertion of 
a unique C1aI site. A Xbal-C1AI- Xbal synthetic oligo 
nucleotide pair was ligated resulting in a plasmid 30, 
pBV116-C1aI. The plasmid 30 is treated by complete diges 
tion with SacI, partial digestion in Nde, followed by frag 
ment isolation, purification, and CIAP treatment to result in 
a fragment 32, a linear fragment of pBV116-C1aI.* 
In FIG. 4, there is shown a conversion of the plasmid 16, 
pBVD79, and the plasmid 18, pBVF2, to the plasmid 
40pBVF2-D79. In this process, the plasmid 18, pBVF2 is 
treated by adding the missing nt at 3'-end to make overlap 
ping with pBVSD2-3' and to restore the DraIII site from the 
NADL by ligating oligo EcoRV-DraIII-BamHI to result in a 
plasmid 34, pbVf2-DraIII. A plasmid 36, pBVF2-D79, is 
prepared by digesting a plasmid 16, pBVD79, with SmaI 
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and AVr, purifying the insert fragment and with ligating 
into a window created in the plasmid 34, pBVF2-DraIII, by 
digesting with HindIII and blunting, then digesting with 
Avril and followed by CIAP treatment. The plasmid 36 is 
treated by adding a unique Sac Site. A Synthetic oligonucle 
otide pair bearing a SacI site flanked by E. coli cohesive ends 
was ligated to form a plasmid 38, pBVF2-D79-SacI, which 
in turn is digested with Nde and SacI. Purifying and 
inserting the fragment to result in a plasmid fragment 40, 
pBVF2-79. The plasmid 42 pBV116-F2, shown in FIG. 6, is 
prepared by combining and ligating plasmid fragment 32, 
shown in FIG. 3 and FIG. 6, pBV116-C1aI, modified by 
removal of a DNA fragment extracted from EcoRV site to 
the RSal Site, followed by replacement with an analogons 
fragment derived from BVDV RNAby RT-PCR and plasmid 
40, pBVF2-D79 modified by removal of a DNA fragment 
extracted from EcoRV site to the RsaII site, followed by 
replacement with an analogons fragment derived from 
BVDV RNA by RT-PCR and ligating to a SacI NdeI (partly 
digested) vector to form the plasmid 42, pBV116-F2. A 
plasmid 44, p3V18-F2, is formed by combining the plasmid 
26, pBV18-T7-C1aI modified by removal of a DNA frag 
ment extracted from EcoRV site to the RsaII site, followed 
by replacement with an analogons fragment derived from 
BVDV RNA by RT-PCR, with the plasmid 42, pBV116-F2, 
using SmaI/Bsu36I (partly digested) ligated to Bsu36I/MscI 
digested vector. 
In FIG. 5, there is shown the conversion of the plasmid 20, 
pBVSD2-3', to the plasmid 50, pBV5D3'-MCUI. In this 
process, a plasmid 46, pBVSD2.3-C1aI is prepared by 
ligating a synthetic DraIII-C1aI/Xba-DraIII oligonucle 
otide in plasmid 20, pBVSD2-3', at a unique DraII site. The 
plasmid 46, p3VSD2-3'-C1a, has the oligonucleotide Aatl 
3'-end SacII-Aat I introduced to restore the missing 
sequences at the 3'-end of RIBV5V genome to form a 
plasmid 48, bBVSD-3". The plasmid 48, pBVSD-3' is con 
verted to a plasmid 50, pBVSD-3'-M1 uI by deleting the T7 
promotor located between the C1 oI and Hsell sites. A 
Synthetic oligonucleotide linker bearing on M1uI recogni 
tion site sequence flanked by ClaI and Hae|I cohesive ends 
was cloned at this location. The plasmid 50 p3VSD-3'-M1 uI 
is converted to the plasmid 52, pBVSD-3'-M1 uI by digest 
ing with DraII and C1aI, and treating with CIAP 
Finally, in FIG. 6 there is shown the conversion of the 
plasmid 32, pBU116-C1aI, and the plasmid 40, PBVF2 
D79, to the plasmid 54, pVV-NADL, which is 14.578 bp in 
length. The plasmid 54 is formed by combining the plasmid 
44, pBV18-F2, with the plasmid 52, pBVSD-3'-M1uI. A 
purified C1a DraIII insert from plasmid 44 was ligated into 
the plasmid 52 previously digested with C1 al/DraII. 
The resulting plasmid, pVVNADL, consists of the full 
length cDNA of the BVDV genome flanked by an upstream 
T7 promoter which directs the start of transcription at 
nucleotide position 1. A SacII recognition Sequence located 
at the end of the BVDV 3'-UTR allows production of 
positive sense RNA molecules of 12578 nucleotides by 
runoff transcription with T7 RNA polymerase. Introduction 
of a Sequence tag into the BVDV genome was performed by 
digesting pVVNADL with DraIII and treating linear DNA 
with T4 DNA polymerase to remove the 3'-overhang. The 
blunt DNA was recircularized with T4 DNA ligase and the 
resulting pVVNADL Dra plasmid was sequenced to verify 
the three-nucleotide deletion. 
To substitute a region of the BVDV, NADL, genome 
encoding the major envelope glycoprotein, transfer vector 
pVVNADL delta SA was constructed deletion of a Sal I 
Aati fragment from pVVNADL, comprising all the non 
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Structural protein-encoding region downstream of the Sa1 I 
site (nucleotides 5621 to 12542). APvulI-XcmI fragment of 
pVVNADLSA including E2/gp53 was replaced using stan 
dard methods with a homologous cDNA fragment derived 
from the Singer strain of BVDV by RT-PCR. The resulting 
pVVNADLA SA-SINgp was digested with C1aI and DraIII 
to isolate a fragment representing the 5'-5184 nucleotides of 
the BVDV genome to be ligated to pSDM1u-3’ digested 
with C1a and DraIII to create the appropriate window. The 
resulting construct was designated pVVNADLSINgp and 
has Singer Strain-derived genomic Sequences from nucle 
otide position 2199 to 3497 replacing the original BVDV 
Strain NADL Sequences. 
RNA transcripts were synthesized in vitro with T7 RNA 
polymerase from a template consisting of the full-length 
cDNA of the BVDV genome contained in pVVNADL 
linearized with SacII and treated with T4 to remove the 
3'-overhang. The RNA was transcribed with bacteriophage 
T7 RNA polymerase under conditions adapted from the 
methods described in F. Ausubel, R. Brent, R. Kingston, J. 
Moore, J. Siedman, J. Smith & K. Struhl (1987) Current 
Protocols in Molecular Biology John Wiley and Sons, New 
York and E. T. Schenbom and R. C. Mierendorf, Jr., (1985) 
Nucleic Acids Res 13, 6223–36. 
Transcription reaction products were analysed by gel 
electrophoresis and Northern analysis, using a probe derived 
from the 5'-end of the BVDV genome. RNA synthesized in 
vitro was digested with RNase-free DNase I, precipitated 
with isopropanol, washed in ethanol and used to transfect 
EBTr cells by electroporation as described below. Controls 
included the electroporation of a transcription mix lacking 
template DNA, or T7 RNA polymerase, or the use of a 
truncated Subgenomic cDNA template (Sal digested). Elec 
troporated cells were distributed into dishes containing glass 
coverslipS to allow acetone fixation and immunostaining for 
fluorescence microScopy. 
Integrity of the open reading frame (ORF) was assessed 
on Bovine Testicle (BT) cells infected with vaccinia MVA 
T7 by transient transfection gene expression. Cells were 
fixed and probed for expression of E2/gp53 or NS23/p 125 
with specific monoclonal antibodies (MAbs). RNA trans 
fection was performed as follows: 
Briefly, 3x10 EBTr cells resuspended in medium con 
taining 3 ug isopropanol-precipitated RNA were electropo 
rated by two consecutive discharges of 1700 V/cm and 25 uF 
in a 0.4 cm cuvette using a Gene Pulser instrument (Bio 
Rad). RNA transfer efficiency was assessed by removing 
coverslipS at 24 and 48 hours after plating and processing for 
immunofluorescence using a MAb to BVDV. Production of 
infectious progeny virus was assessed by harvesting culture 
medium from transfected monolayers, filtering through 0.45 
urn membranes and inoculation onto BT cells. Infection of 
BT cells was monitored by development of cytopathology 
and immunostaining with Specific Mabs. Stocks of 
transfection-rescued virus were prepared after three in Vitro 
passages to be used to determine genotype and phenotype. 
Phenotype analyses of all plasmid-derived viruses were 
carried out on StockS prepared after three cell culture pas 
Sages and included plaque morphology, as well as growth 
kinetics analyses at three incubation temperatures, 35 C., 
37 C. and 39.5 C. by standard protocols. Antigenic analy 
SeS included Seroneutralization assays and immunofluores 
cence probing using a panel of 9 MAbs which recognize 
E2/gp53 polymorphisms or conserved EO/gp48 apitopes. 
Bovine testicle cells were infected with BVDV at an input 
multiplicity of five and the monolayers lysed at 18 hours 
after infection for RNA extraction. RT PCR was performed 
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with appropriate Synthetic oligodeoxynucleotide primer 
pairs. DNA amplified with Taq DNA polymerase was 
Sequenced. 
In Summary, two plasmids were constructed, each carry 
ing cDNA representing approximately the 5'- and 3'-halves 
of the BVDV genome. Plasmid pBV18-F2 consists of a T7 
RNa polymerase promoter abutted to the viral 5'-UTR and 
adjacent polyprotein ORF Sequences encoding the viral 
structural proteins. The second plasmid pBV50M1u-3' 
encompasses the nonstructural protein region and the 
3'-UTR of the BVDV genome followed by a SacII restric 
tion endonuclease Site. These plasmids were used to join the 
two halves of the viral genome to give rise to a genomic 
length construct termed pVVNADL. 
The integrity and continuity of the polyprotein ORF was 
assessed by T7-driven transient expression of transfected 
pVVNADL DNA. Cells previously infected with vaccinia 
virus MVA-T7 expressing T7 RNA polymerase and trans 
fected with pVVNADL DNA showed bright immunofluo 
rescence following Staining with Mabs to Structural or 
nonstructural viral proteins, revealing expression of genuine 
BVDV proteins from an uninterrupted polyprotein ORF. 
The plasmid carrying the entire genome of BVDV, 
pVVNADL, contains the Co1E1 replicon derived from 
pGEM4 and is 14,578 bases in length. The plating efficiency 
of E. coli, strain GM119 or JM109, hosts transfected with 
Supercoiled pVVNADL DNA on amplicillin-containing solid 
medium is more than 100-fold lower than that of cells 
receiving pCEM4 DNA. E. coli strain GM119 proved to be 
a more suitable host for pVVNADL than strain JM109 
which led to frequent DNA deletions. 
Runoff RNa transcripts synthesized in vitro with phage T7 
RNA polymerase from SacII-linearized pVVNADL were 
largely Subgenomic in size with only a minor proportion of 
BVDV genome-length RNA molecules. Transfection of this 
unselected heterogeneous population of transcripts into 
EBTr cells by electroporation resulted in typical BVDV 
cytopathology, Such as vacuolation and detachment from the 
matrix, after 72 hours. In contrast, EBTr cells transfected 
with truncated Subgenomic transcripts processed in the same 
fashion did not show these changes. Expression of Structural 
and nonstructural BVDV proteins was observed in 1-3% of 
the EBTr cell population as early as 24 hours after trans 
fection by immunofluorescence with BVDV-specific MAbs. 
The proportion of positive cells rose to 10-20 percent by 48 
hours following transfection. 
Cell culture fluids were harvested periodically and used 
for the propagation of the rescued infectious virus on bovine 
testicle (BT) cells to carry out genetic and phenotypic 
characterization. Culture Supernatants from EBTr cells 
transfected with pVVNADL-templated transcripts caused 
cytopathic changes in bovine testicle BT cells 48 hours after 
inoculation, while cell culture medium from control EBTr 
monolayerS transfected with truncated transcripts had no 
effect. The antigenic phenotype of the virus rescued from 
pVVNADL transcripts, termed i-VVNADL, was identical to 
the parental NADL virus by immunofluorescence Straining 
with a panel of Mabs against the E2/gp53 envelope glyco 
protein and EO/gp48. 
Growth parameters of the i-VVNADL at different tem 
peratures were indistinguishable from parental BVDV 
NADL virus by plaque morphology and kinetics of growth 
determined at 35° C., 37° C., and 39.5° C. Thus, BVDV 
rescued from pVVNADL is essentially identical to the 
parental NADL strain of BVDV in vitro. Genetic manipu 
lations of the NADL strain of BVDV involving the creation 
of BVDV clNA plasmid intermediates propagated in E. coli 
does not alter the in vitro phenotype of the resulting 
i-VVNADL. 
6,001,613 
The introduction of a sequence tag into the BVDV 
genome allows unambiguous identification of the viruses 
rescued from plasmid-derived RNA transcripts and facili 
tates the interpretation of experimental data. The model tag 
should ideally be a unique Sequence, readily identifiable by 
restriction fragment length polymorphism analysis and be 
neutral with respect to the viral phenotype. A deletion was 
introduced in the pVVNADL infectious clone which results 
in loSS of a Dral restriction enzyme recognition Site and 
gain of a PmlI recognition site. 
An infectious virus was rescued from pVVNALDL Dra 
templated transcripts with the same kinetics as with the 
intact WT cDNA infectious clone, the transfected cells 
showed a large proportion of infected cells by immunofluo 
rescence of coverslipS fixed at 48 hours. Characteristic 
vacuolating cytopathology could be observed in transfected 
cells between 72-96 hours after transfection and in Subse 
quent passages of the culture medium onto new BT cells. 
Restriction enzyme analysis of a 183 base pair amplicon 
spanning the DraIII site amplified by RT-PCR from 
i-VVNADL Dra revealed the presence of a PmlI site 
(CACGTG) and the absence of a Dram site (CACagaGTG). 
In contrast, DNA amplified from parental virus showed the 
reciprocal Susceptibility to cleavage with these enzymes, 
characteristic of the NADL strain of BVDV. Antigenic 
analysis reveals that the i-VVNADL Dravirus is essentially 
identical to the parental NADL virus as ascertained by MAb 
analyses. Growth properties of i-VVNADL Dra analyzed in 
vitro were similar to those of WT. Thus, the single amino 
acid deleted from the vicinity of the putative cleavage Site 
within p125/NS23 did not affect its viability and phenotype 
in vitro. 
Reverse genetic approaches may be used to construct 
chimeras of viral genomic RNA for identification of 
genomic Sequences responsible for a given phenotypic char 
acter. Antigenic chimeras of BVDV prototype NADL strain 
with the widely used strain Singer were constructed for this 
purpose. Unique markers are present exclusively in each of 
the two parental Strains and were used to identify the newly 
created chimeric virus only if it carried both markers. One 
marker, a unique 270 base Stretch of Sequence derived from 
the cattle genome at position 4993, is characteristic of the 
NADL strain of BVDV. The other marker consisted of 
unique amino acid Sequences of the E2/gp53 envelope 
glycoprotein which confer the Singer Strain reactivity with 
Mabs 20, 31, 32, and 39 by immunoassay and neutralization. 
Thus, the Singer strain does not have the 270 nucleotide 
insert while the NADL strain fails to react with the selected 
set of four MAbs. 
By replacing the original envelope glycoprotein in the WT 
infectious clone with Sequences coding for the Singer enve 
lope genes, a chimeric virus which will carry the epitopes 
present in the Singer Strain envelope and the 270 nucleotide 
bovine insert at position 4993 is obtained. The pVVNADL 
PvuII-XcmI fragment (position 2199 to 3497) which 
encodes for the C-terminus of E1/gp25 and the entire 
ectodomain of E2/gp53 was substituted with homologous 
sequences from the Singer strain of BVDV giving rise to 
plasmid pVVNADLSINgp. An infectious chimeric BVOV 
was recovered from transcripts derived from pVVNADLS 
INgp. Plaque morphology and growth kinetics of the chi 
meric virus, termed i-VVNADLSINgp, revealed that its 
growth properties are virtually identical to its parental 
NADL Strain virus. By contrast, the antigenic properties of 
the chimeric virus depart from the BVDV strain NADL 
ancestor. The pattern of reactivity of proteins encoded by 
i-NADLSINgp with a panel of E2/gp53 with an antigenic 
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profile identical to the Singer isolate by immunofluores 
cence. Subtle differences were observed between these 
viruses in neutralization titers with Mabs 10 and 39, but the 
overall patterns remained the same. 
The virus recovered from the parental pVVNADL clDNA 
has a gp53 indistinguishable from that of the NADL strain. 
Nucleotide sequence analyses of the i-VVNADLSINgp chi 
meric virus genomic RNA across the Substituted fragment 
and the flanking regions reveals the chimeric structure of the 
genome. Furthermore, the 270 nucleotide bovine Sequence 
insert at nucleotide 4993 characteristic of the NADL strain 
is present in i-VVNADLSINgp chimeric virus genomic 
RNA, as indicated by the size of the amplicon obtained by 
RT-PCR. Thus, the experimental evidence indicates that 
i-VVNADLSINgp represents a chimeric virus consisting of 
a genomic backbone from NADL strain of BVDV, but 
expressing the Singer Strain E2/gp53 glycoprotein as well as 
the C-terminal end of E1/gp25. 
The simple observation that uncapped RNA transcripts 
produced by T7 RNA polymerase from pVVNADL template 
establishes three concepts. The first concerns the Structure of 
the 5'- end of the viral RNA. RNA without a 5'-cap structure 
was infectious, Suggesting that a cap-independent translation 
initiation mechanism is used by BVDV genomic RNA for 
gene expression. This result is compatible with biochemical 
evidence Suggesting that the 5'- end of genomic RNA was 
not blocked by inverted methylguanosine. The Second con 
cept emerges as a corollary of the first. An internal ribosome 
entry site element in the 5'-UTR of the BVDV genome 
identified in reticulocyte lysates must be functional during 
virus infection of cells. The third concept relates to the 
sequences of the extreme 5’- and 3'-temini of the viral RNA, 
thought to contain minus and plus Strand RNA replicase 
promoter elements, respectively. Technical difficulties are 
commonly encountered in approaches to determine the 5'- 
and 3'-termini of large viral RNA molecules. However, the 
sequences reported by Deng and Brock, “5' and 3' Untrans 
lated Regions of Pestivirus Genome: Primary and Secondary 
Structure Analyses,” Nucleic Acids Research, 1993, Vol 21, 
No. 8, 1949–1957, and incorporated in pVVNADL gave rise 
to infectious virus with WT phenotype, indicating their 
functionality for the first time. 
The 12,578 bases long genome of BVDV constitutes one 
of the largest known positive strand viral cDNA clone which 
yields infectious RNA transcripts. Moreover, the cDNA 
clone is replicated as a single plasmid in E. coli. The plating 
efficiency of E. coli hosts, such as strain JM109, transformed 
with pVVNADL and its derivatives and plated on amplicillin 
Selective medium was reduced by at least 2 orders of 
magnitude as compared to the pGEM4 vector alone. In 
addition, a high frequency of deletions in transformant Strain 
JM109 E. coli was observed. Instability of large cDNA 
clones is not uncommon and often determines utilization of 
alternative Strategies involving generation of transcription 
DNA templates in vitro by ligation or long PCR. However, 
we found that certain strains of E. coli, notably GM119, 
circumvented Such difficulties. The basis or biochemical 
correlates of the greater stability of pVVNADL in this host 
are unknown. 
Full-length runoff transcripts were produced in vitro with 
low efficiencies by T7 RNA polymerase, apparently due to 
the intrinsic properties of the 12.5 kB pVVNADL template. 
Although the T7 RNA polymerase is highly processive for 
elongation of Shorter transcripts, certain Secondary Struc 
tures in nascent transcripts can act as termination Signals. 
The probability of such fortuitous events increases with 
transcript length. The presence of discrete Subgenomic 
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length RNA molecules was sometimes observed in electro 
pherograms of transcription reaction products. Low yields of 
full-length transcripts are not uncommon and also occur in 
other pestivirus cl)NAS as shown for hog cholera virus in 
two independent reports. Unfractionated transcription prod 
ucts yielded infectious viruses readily upon transfection. 
Because only a relatively minor population of transcripts is 
full-length, it is likely to have a high Specific infectivity. 
Others have reported considerably longer delays before an 
infectious virus is recovered from transfected monolayers. 
The in vitro phenotype of the virus rescued from the 
pVVNADL as defined by the parameters and characteristics 
Studied did not depart significantly from those of the paren 
tal BVDV strain NADL. Interestingly, shuttling of the large 
BVDV RNA genome through cDNA in a prokaryotic plas 
mid did not result in changes of the Viral phenotype in vitro. 
Animal inoculation Studies will be required to determine if 
the same is true of the in vitro phenotype of i-VVNADL. 
The wild-type nature of the virus rescued from pVVNADL 
makes it an ideal backbone to engineer changes leading to 
attenuation by reverse genetic approaches. 
The high plasticity that characterizes RNA genomes 
makes it useful to design genomic tags that consist of more 
than Single nucleotide changes to avoid reversion. However, 
large insertions or deletions may result in major decreases in 
replication fitness, favoring emergence of genomes repaired 
by RNA recombination. A deletion of three nucleotides 
(5182–5184: codon 1600) within the 270 nucleotide insert 
present in the NS23 coding region of the genome was used. 
Presence of this bovine sequence element at nucleotide 4993 
is correlated with proteolytic processing of NS23, and the 
latter coincides with Viral cytopathogenicity and virulence. 
Infection of BT cells with the tagged i-VVNADL Dra 
Virus resulted in cell death with the same kinetics and 
features of the parental Strain. Thus, glutamic acid at posi 
tion 1600 in the NADL strain polyprotein is not important 
for Viral cytopathogenicity. However, this deletion resulted 
in a convenient restriction fragment length polymorphism 
tag providing a convenient means to discriminate between 
WT and tagged genomes. Although the virulence of this 
Virus in cattle has not been determined experimentally 
(observed), its in vitro properties are identical to the WT. 
Therefore, i- VVNADL Dra constitutes a good candidate 
virus with a neutral genomic tag to further examine BVDV 
pathogenicity. 
The glycoprotein chimera of BVDV displays a unique 
antigenic phenotype without alterations in replication prop 
erties in vitro. This virus can simply be traced using two 
markers: the unique epitopes present in E2/gp53 of the 
Singer strain of BVDV detected with specific Mabs (e.g. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS : 1 
<21 Oc 
<211 
<212> 
<213> 
SEQ ID NO 1 
LENGTH 14578 
TYPE DNA 
ORGANISM: bovine viral diarrhea virus 
<400 SEQUENCE: 1 
cacgc gitatic gatgaattcg ttaatacgac to actatagt attacga gaat tagaaaaggc 
acticgtatac gitattgggca attaaaaata ataattaggc citagg galaca aatc.ccitcto 
agcigaaggcc gaaaagaggc tagcc at gcc cittagtagga citagcataat gaggggggta 
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10f) and the presence of a unique 270 base pair bovine 
sequence insert after nucleotide 4993, detected by PCR, 
characteristic of the NADL parent and absent in the Singer 
genome. 
Neutralization of virus infectivity by Mabs results from a 
high-affinity interaction between glycoprotein and antibody 
(Ka values between 10 and 10' 1-mo1-'). Even minor 
conformational changes in the Viral glycoprotein can lower 
the affinity of the interaction (10 to 107 1.m01-') and 
impair neutralization without preventing binding in immu 
noassays. Mabs 10 and 39 neutralized the chimeric virus to 
a lesser extent as compared to the WT BVDV Singer, 
Suggesting extramolecular influences on the interaction 
between the Mab IgG and E2/gp53. For example, the 
structure of the E2/gp53 may be affected by association with 
a different E1/gp25 he tero dimer partner in 
i-VVNADLSINgp leading to a decreased interaction affin 
ity. Mabs 10 and 39 reacted with the chimeric virus in 
immunofluorescence assays, in accordance with the well 
established lower Stringency of this assay. 
Reverse genetics approaches can be used to introduce 
Specific alterations or tags into the BVDV genome, as 
exemplified by the deletion of codon position 1600 
(glutamic acid). Moreover, construction of chimeric virus is 
also feasible, as evidence by the expression of an envelope 
glycoprotein from a different BVDV strain. The two main 
approaches to explore gene function in positive Strand RNA 
Virus can now be implemented using infectious cDNA 
clones of BVDV. 
Although the upper size limits of viable BVDV genomes 
are unknown, at least 2 KB of additional coding Sequences 
can be part of viable virus. Consequently, it may be possible 
to use BVDV as a vector to express foreign proteins for 
immunization purposes. It will be of interest to determine if 
interspecies chimeras with other pestivirus or hepatitis C and 
G Virus are viable. Precedents exist in picornavirus and 
flavivirus Supporting the notion that different viral functional 
units can be substituted with those of distantly related virus. 
Notably, the hepatitis C internal ribosome entry site element 
is functional in poliovirus-hepatitis C chimeras (56). These 
chimeric approaches could lead to understanding of in Vitro 
host range in pestivirus and hepatitis C virus. Finally, 
infectious clones could be used to engineer attenuating 
mutations leading to development of novel live vaccines. 
Although a preferred embodiment of the invention has 
been described with Some particularity, many modifications 
and variations of the preferred embodiment are possible in 
the light of the above teachings. It is to be understood that, 
within the Scope of the appended claims, the invention can 
be practiced other than as Specifically described. 
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accacttgga 
tgcgaagatg 
atcttgcata 
aa.gcaa.gagg 
gccaaaccola 
atgg tatgcc 
ttagccacaa 
tgitatcacco 
acttgttgttgc 
tgtggctato 
ttggagaacg 
gccatagitac 
gctatogata 
gggCCtgtag 
tittgagcc.ca 
tittgacctgg 
gtag tag.ccc 
to agaacaga 
ttgctaacco 
agggaggaga 
atcaaatctg 
ggcCaagagt 
ggitttaatca 
citgagggtoa 
ataa.cccitac 
tgcattctda 
atc.gagatgc 
ttgatctoaa 
tgtgtgccita 
atcctgccta 
gaaagaagtt 
gaga.gtggag 
atactcittgc 
atatacatga 
gagatctoag 
tggtocatgg 
ttgaga aacc 
gaggaggaag 
alaga gCaggC 
tgcc caaaat 
aggaatactic 
ggaagttaat 
caagagccitt 
atgtag toga 
tagtaagagg 
ccataggatg 
citgtggtacg 
aaaagaatct 
citggagacca 
aatttaaaga 
agacitggitta 
cacaagggiac 
ccaaactcgg 
aaaaga cago 
gag acagota 
aggtgactga 
tottgggtgg 
aggccittagg 
ataacaatat 
gcqtaaagaa 
taattgttgat 
actitggggaa 
tagctagg.cg 
citgaactgac 
tgatggittag 
gcc togtatc 
cagaggtaac 
caacaattgt 
tottattgct 
cctatogaatt 
ggctaggggg 
agggcgtata 
cc cittatcaa. 
gttacttaac 
gaggtaccala 
aagaagagga 
taataataaa. 
totacggitat 
actgcataat 
gtggacgc.ca 
15 
acctggaatg 
gtacctocaa 
gcc gaccagt 
aatgaacgac 
gaagttcaat 
gacagggact 
gacatataga 
gggggaggat 
actactatac 
gagtgaggga 
caggctagta 
attaaagtgc 
accitatgcct 
gtgtacttitc 
citttcagdaa 
ccatcaccgg 
cagatatgta 
gattcagtat 
tgaagtggtg 
gtgggtotta 
cct actogatg 
aatagaccitc 
tgacccaact 
ccaccagoct 
citatgtgaca 
tgcggtgttc 
taticccaaac 
aac gaggtgg 
ggtoacalacc 
ggittaaatta 
gatagacitat 
totttittc.ca 
agcaa.cactg 
tittgg actitt 
catalatatoc 
gag caaaggc 
acatalaggta 
gccaaagatc 
atgcactgta 
tgggalagcc.g 
aagctggaag 
agatgcacga 
gtgg tattoa 
aactittgaat 
acaacgctoc 
gtaagct gta 
aggtotaaac 
ctic catalact 
alaagggggct 
citaccacact 
gacagtacct 
aagataggaa 
tgcagaccat 
alactacacta 
tacatgctaa 
gattactitcg 
citttggittac 
ggatcagggg 
acatactitct 
citctitat acc 
attggggatg 
tgttttacaa 
atagt gccac 
ggagttgaca 
gattattitta 
ttgataagaa 
tggagaccac 
aaggttgacg 
ttgtggg.ccg 
tactatotga 
acaagagttg 
tdaaggcaga 
ataagttgcg 
atgtactaca 
aggittagtgg 
ttaaagaagt 
aggaatgaga 
atgactataa 
tgtgagggCC 
ataacgtgtg 
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acacaatggit 
gagaalaccag 
aaaaacticitt 
ttggacitctg 
tgaacgg acc 
cgtcattcaa 
cattcc.ctica 
gcatccttgg 
citattgaatc 
acco cattgg 
cittgcaatag 
aaacaactot 
atgaaatcat 
agacattaaa 
aaggagagta 
citgagtc.cat 
tggttacata 
aagtggtgat 
tgctgct gta 
acatcttagt 
tggtaaaggc 
cagtag tact 
tggtaacaat 
togctgtggc 
gatataaaaa 
gcctaatata 
talactittaat 
tggctggcct 
actitcttaac 
aaactgttag 
actic catcta 
aag Cacaggg 
to agcagtaa 
tgcacaggaa 
cagdacticat 
tittatctatt 
cc.gtggcttic 
tdaaggc.ca.g 
gaga.gtggaa 
ggatgtc.gct 
cattgcttgg 
atatotogca 
tgatggg.cga. 
cc catgtgat 
ggcct tccag 
tatggacacc 
taggcaaggc 
aggaaattgg 
ttgcaagtgg 
caagtgtaaa 
agalaggtgtg 
acaggtoata 
atcaagtgag 
aaataagtat 
tdaatactgg 
attagtggtg 
catggtotta 
gatgggcaac 
cctactgctg 
ggtacaccca 
cgatticaggg 
aatcgtoata 
aatgg cago a 
ggtoatgact 
atggittacag 
ccitaggtaga 
actattatat 
attgttgcaa 
cctaatactg 
gactgataca 
cgacgttgat 
gaatttittct 
atggcagcta 
agittatagaa 
agagctgaac 
gtctggalagg 
ttggtacggg 
tacactgagt 
aggtogCacc 
agcagattitt 
264 O 
27 OO 
276 O. 
282O 
2880 
2.940 
3060 
312 O 
318O 
324 O 
3360 
342O 
3480 
354. O 
3600 
3660 
372 O 
378 O. 
384 O 
39 OO 
396 O 
4020 
408 O 
414 O 
4200 
4260 
4320 
4.380 
4 440 
4500 
45 60 
4680 
474. O 
4800 
4860 
4920 
4.980 
16 
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-continued 
tgcgittatcc cct gattctg toggata accg tattaccgcc tittgagtgag citgat accgc 
togcc.gcago C galacga.ccg agcgcagoga gtcagtgagc gaggaag.cgg aagagcgc 
The following is claimed: 
1. A method of producing recombinantly engineered 
infectious bovine Viral diarrhea virus comprising: 
providing a vector comprising a reverse transcribed copy 
of bovine viral diarrhea virus RNA; 
recombinantly engineering the reverse transcribed copy 
of the bovine viral diarrhea virus; 
transforming an E. coli with the vector; 
causing the transformed host cell to produce a plurality of 
Vectors, 
extracting the plurality of vectors from the transformed 
host cell; 
forming a plurality of synthesized RNA from the plurality 
of vectors comprising the reverse transcribed copy of 
the bovine viral diarrhea virus RNA; 
introducing the Synthesized RNA into a mammalian cell; 
and 
recovering the recombinantly engineered infectious 
bovine viral diarrhea virus from the mammalian cell. 
2. The method of claim 1 wherein the E. coli is strain 
GM119. 
3. The method of claim 1 wherein the step of introducing 
the bovine viral diarrhea virus RNA into the mammalian cell 
utilizes electroporation. 
4. The method of claim 1 wherein the mammalian cell is 
an embryonic bovine tracheal cell. 
5. The method of claim 1 wherein the vector comprises 
pVVNADL-SINgp. 
6. The method of claim 1 wherein the vector contains a 
Selective marker for transformed cells. 
7. The method of claim 1 wherein the vector comprises 
pVVNADLADra. 
8. A method of producing recombinantly engineered 
infectious bovine Viral diarrhea virus comprising: 
providing a vector comprising a reverse transcribed copy 
of bovine viral diarrhea virus RNA; 
recombinantly engineering the reverse transcribed copy 
of the bovine viral diarrhea virus to form a recombi 
nantly engineered vector; 
transforming E. coli, strain GM119, with the recombi 
nantly engineered vector; 
causing the transformed E. coli to produce a plurality of 
the recombinantly engineered vectors; 
extracting the plurality of recombinantly engineered vec 
tors from the transformed E. coli, 
forming a plurality of synthesized RNA from the plurality 
of recombinantly engineered vectors comprising the 
reverse transcribed copy of bovine viral diarrhea virus 
RNA; 
introducing the synthesized RNA into an embryonic 
bovine tracheal cell by electroporation; and 
recovering the recombinantly engineered infectious 
bovine viral diarrhea virus. 
9. A method of isolating a plurality of recombinantly 
engineered bovine viral diarrhea virus comprising: 
providing a vector comprising a reverse transcribed copy 
of a genome of bovine viral diarrhea virus RNA; 
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creating a recombinantly engineered infectious bovine 
viral diarrhea virus; 
causing a host cell to produce a plurality of recombinantly 
engineered infectious bovine viral diarrhea virus, and 
isolating the plurality of recombinantly engineered bovine 
viral diarrhea virus. 
10. A method of producing recombinantly engineered 
infectious bovine Viral diarrhea virus comprising: 
providing a pVVNADL, 
recombinantly engineering pVVNADL to form a recom 
binantly engineered pVVNADL, 
transforming E. coli, strain GM119, with the recombi 
nantly engineered pVVNADL to form a transformed E. 
coli, 
causing the transformed E. coli to produce a plurality of 
the recombinantly engineered pVVNADL, 
extracting the plurality of recombinantly engineered 
pVVNADL from the transformed E. coli, 
forming a plurality of synthesized RNA from the plurality 
of recombinantly engineered pVVNADL, 
introducing the plurality of synthesized RNA into an 
embryonic bovine tracheal cell by electroporation; and 
recovering the recombinantly engineered infectious 
bovine viral diarrhea virus. 
11. An isolated vector adapted to produce recombinantly 
engineered infectious bovine viral diarrhea virus. 
12. The vector of claim 11, further comprising a Sequence 
tag. 
13. A chimeric vector comprising a 270 nucleotide insert 
and an envelope glycoprotein from Singer Strain bovine viral 
diarrhea virus wherein the vector is adapted to produce a 
chimeric infectious bovine viral diarrhea virus. 
14. The vector of claim 13 wherein the vector comprises 
pVVNADL-SINgp. 
15. The vector of claim 13, wherein the synthesized RNA 
is introduced into EBTr cells. 
16. An isolated vector comprising sequence ID. N.O. 1. 
17. A vector comprising pVVNADL-SINgp. 
18. A vector comprising pVVNADLADra. 
19. A chimeric virus comprising i-VVNADL-SINgp. 
20. A recombinant bovine viral diarrhea virus comprising 
i-VVNADLADra. 
21. A plurality of recombinantly engineered infectious 
bovine viral diarrhea virus produced by the proceSS com 
prising: 
providing a vector comprising a reverse transcribed copy 
of a genome of bovine viral diarrhea virus RNA; 
creating a recombinantly engineered infectious bovine 
viral diarrhea virus; 
causing a host cell to produce a plurality of recombinantly 
engineered infectious bovine viral diarrhea virus, and 
isolating the plurality of recombinantly engineered infec 
tious bovine viral diarrhea virus. 
